Tianjin Zhong Xin Pharmaceutical Group Corporation has reported earnings of RMB213 million ($43.5 million) for its 1QFY2021 ended March, up 25% y-o-y.

The higher earnings follow an increase in revenue for the period, which climbed 10% y-o-y from RMB1.65 billion to RMB1.83 billion on the back of higher sales in tandem with China’s recovering economy.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.

Bonus:

  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply

Subscribe

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook